184.6K XNAS Volume
XNAS 24 Mar, 2025 5:30 PM (EDT)
Inotiv Inc Key Metrics
Select
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTLow rank
6Positive15Negative
28.6% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Inotiv Inc Stock Price Analysis
Day Price Range | 2.9 (LTP) 2.82.9 LowHigh |
Week Price Range | 2.9 (LTP) 2.73.4 LowHigh |
Month Price Range | 2.9 (LTP) 2.34.3 LowHigh |
52 Week Price Range | 2.9 (LTP) 1.211.4 LowHigh |
Inotiv Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Hit
Inotiv Inc's Revenue was higher than average estimate 2 times in past 3 years
EPS forecast
Current EPS
Avg. Estimate
Hit
EPS is expected to grow by 41.8% in FY25
Consensus Recommendation
3 ANALYST Recommendations
BUY
The consensus recommendation from 3 analysts for Inotiv Inc is BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Inotiv Inc Stock Analysis
Inotiv Inc stock analysis with key metrics, changes, and trends.
Inotiv Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $490.74 M | 14.27% | negative |
| |
Annual Net Profit | $108.44 M | 3.14% | negative |
| |
Price to Earning Ratio | -0.81 | - | negative |
| |
Stock Price | $2.90 | -72.74% | negative |
| |
Quarterly Revenue | $119.88 M | 11.53% | negative |
| |
Quarterly Net profit | $27.63 M | 79.56% | negative |
| |
Debt to Equity Ratio | 2.61 | - | negative |
| |
Return on Equity(ROE) | -49.33 % | -49.33% | negative |
| |
Mutual Fund Holding | 14.41 % | 0.91% | positive |
| |
Promoter Share Holding | 30.52 % | 6.57% | positive |
| |
Interest Coverage Ratio | -1.79 | - | negative |
| |
Institutional Holding | 29.70 % | 0% | neutral |
|
Loading data..
Inotiv Inc - Company Profile
What does Inotiv Inc do?
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Inotiv Inc Management structure
All Gross Remunerations are in USD
Inotiv Inc Board of directors
All Gross Remunerations are in USD